Cancer Medicine (Apr 2019)

Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors

  • Laura V. Klotz,
  • Yves Courty,
  • Michael Lindner,
  • Agnès Petit‐Courty,
  • Anja Stowasser,
  • Ina Koch,
  • Martin E. Eichhorn,
  • Ioannis Lilis,
  • Alicia Morresi‐Hauf,
  • Kristina A. M. Arendt,
  • Mario Pepe,
  • Ioanna Giopanou,
  • Giannoula Ntaliarda,
  • Sabine J. Behrend,
  • Maria Oplopoiou,
  • Valérie Gissot,
  • Serge Guyetant,
  • Sylvain Marchand‐Adam,
  • Jürgen Behr,
  • Jan‐Christian Kaiser,
  • Rudolf A. Hatz,
  • Anne‐Sophie Lamort,
  • Georgios T. Stathopoulos

DOI
https://doi.org/10.1002/cam4.2031
Journal volume & issue
Vol. 8, no. 4
pp. 1486 – 1499

Abstract

Read online

Abstract A comprehensive characterization of lung adenocarcinoma (LADC) clinical features is currently missing. We prospectively evaluated Caucasian patients with early‐stage LADC. Patients with LADC diagnosed between 2011 and 2015 were prospectively assessed for lung resection with curative intent. Fifty clinical, pathologic, radiologic, and molecular variables were recorded. Patients were followed till death/study conclusion. The main findings were compared to a separate cohort from France. Of 1943 patients evaluated, 366 were enrolled (18.8%; 181 female; 75 never‐smokers; 28% of registered Bavarian cases over the study period). Smoking and obstruction were significantly more prevalent in GLAD compared with adult Bavarians (P 7.5 and 3.6 years, respectively. Patients aged 65 years, resected >60 days postdiagnosis, with abnormal FVC/DLCOVA, N2/N3 stage, or solid histology had significantly decreased survival estimates. These were fit into a weighted locoregional LADC death risk score that outperformed pTNM7 in predicting survival in the GLAD and in our second cohort. We define the clinical gestalt of locoregional LADC and provide a new clinical tool to predict survival, findings that may aid future management and research design.

Keywords